Sol-Gel Technologies Ltd. (SLGL) |
|
4.68 0.13 (2.86%)
|
12-05 15:59 |
|
Open: |
4.55 |
Pre. Close: |
4.55 |
|
High:
|
4.7 |
Low:
|
4.55 |
|
Volume:
|
6,347 |
Market Cap:
|
108(M) |
|
|
|
Technical analysis |
as of: 2022-12-06 9:22:01 AM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 5.76 One year: 6.07 |
| Support: |
Support1: 4.5 Support2: 3.74 |
| Resistance: |
Resistance1: 4.93 Resistance2: 5.19 |
| Pivot: |
4.79  |
| Moving Average: |
MA(5): 4.68 MA(20): 4.8
MA(100): 5.34  MA(250): 6.11 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 23.4 %D(3): 25.7 |
| RSI: |
RSI(14): 42.6 |
| 52-week: |
High: 8.51 Low: 3.94 |
| Average Vol(K): |
3-Month: 6 (K) 10-Days: 6 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SLGL ] has closed above bottom band by 22.4%. Bollinger Bands are 54% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 36 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.7 - 4.73 |
4.73 - 4.75 |
|
Low:
|
4.5 - 4.52 |
4.52 - 4.54 |
|
Close:
|
4.64 - 4.68 |
4.68 - 4.72 |
|
Company Description |
|
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel. |
Headline News |
Fri, 02 Dec 2022
Is Sol Gel Technologies Ltd (SLGL) Stock Worth a Buy Friday? - InvestorsObserver
Wed, 16 Nov 2022
FY2022 EPS Estimates for Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Cut by HC Wainwright - MarketBeat
Thu, 10 Nov 2022
Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Yahoo Finance
Mon, 07 Nov 2022
What Does Sunshine Biopharma’s Acquisition Of Nora Pharma Mean For The Generic Prescription Drugs Market? - Yahoo Finance
Mon, 26 Sep 2022
Sol-Gel Technologies (NASDAQ:SLGL shareholders incur further losses as stock declines 14% this week, taking one-year losses to 46% - Simply Wall St
Fri, 09 Sep 2022
3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
23 (M) |
| Shares Float |
8 (M) |
|
% Held by Insiders
|
74 (%) |
|
% Held by Institutions
|
13.9 (%) |
|
Shares Short
|
123 (K) |
|
Shares Short P.Month
|
128 (K) |
Stock Financials |
|
EPS
|
0.41 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
2.18 |
|
Profit Margin (%)
|
28.9 |
|
Operating Margin (%)
|
26.5 |
|
Return on Assets (ttm)
|
10.8 |
|
Return on Equity (ttm)
|
21.3 |
|
Qtrly Rev. Growth
|
279.1 |
|
Gross Profit (p.s.)
|
0.47 |
|
Sales Per Share
|
1.43 |
|
EBITDA (p.s.)
|
0.41 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-3 (M) |
|
Levered Free Cash Flow
|
-4 (M) |
Stock Valuations |
|
PE Ratio
|
11.14 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
2.14 |
|
Price to Sales
|
3.26 |
|
Price to Cash Flow
|
-37.72 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
